MERKEL CELL CARCINOMA

This study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded t…

This study tested a new radioactive drug (225Ac-SSO110) combined with standard treatments for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to find a safe dose and see if the drug shrank tumors. However, the trial was stopped early after enrol…

This early-phase study tested a new drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limit…

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, and lung cancer. The trial enrolled 77 adu…

This early-phase study tested a new drug, BT-001, injected directly into tumors of people with advanced solid cancers (like melanoma or lung cancer). Some participants also received the immunotherapy pembrolizumab. The goal was to check safety and find the right dose. The study w…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…